General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company.
GE GE +0.99% said current shareholders would get one share in the new GE HealthCare Technologies Inc. for every three shares they hold in GE. The separation is set for Jan. 3 after the markets close, and the new shares will trade on Nasdaq under the symbol GEHC.
The share distribution ratio doesn’t necessarily determine the value of the spinoff when the shares begin trading. Wall Street analysts estimates vary on the value of the business as a public company.
The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.
GE HealthCare, which makes MRI machines and other medical equipment, has about $18 billion in annual revenue, compared with GE’s $74.2 billion in 2021. GE’s healthcare division plans to hold an investor day on Dec. 8.
GE will distribute at least 80.1% of the division’s shares with GE retaining the rest. GE’s CEO Larry Culp will be nonexecutive chairman of the new board, and GE HealthCare CEO Peter Arduini will also be a director.
GE shares have fallen about 9% so far this year, compared with a 14.4% drop in the S&P 500 index.
Based on Wednesday’s share closing price of $85.97, GE has a market capitalization of around $93.6 billion, which would value the healthcare spinoff at about $31.2 billion. The record date for the distribution is Dec. 16.
By Thomas Gryta
Source: wsj.com
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
